“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Cantargia
Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on NSCLC and pancreatic cancer. The most advanced trial is in Phase II.
Cantargia — 8 videos in collection
Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. Its lead asset nadunolimab (CAN04) is being investigated as a treatment for several types of solid tumours across a broad programme; the most advanced indications are non-small cell lung cancer and pancreatic cancer. CAN10, the company’s second lead asset, is being developed for autoimmune diseases. In this video, Cantargia’s chief executive officer Göran Forsberg provides an update on the recently announced rights issue and key clinical highlights.
Get access to the very latest content matched to your personal investment style.
